KALA BIO, Inc. (NASDAQ:KALA) CEO Sells $44,093.77 in Stock

KALA BIO, Inc. (NASDAQ:KALA) CEO Mark T. Iwicki sold 5,779 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

KALA BIO Stock Performance

Shares of KALA stock opened at $6.82 on Thursday. The firm has a market cap of $31.44 million, a price-to-earnings ratio of -0.55 and a beta of -2.11. KALA BIO, Inc. has a 52-week low of $4.21 and a 52-week high of $9.25. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 3.18. The company’s 50 day moving average is $6.71 and its 200 day moving average is $6.32.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.43) by $0.50. On average, sell-side analysts anticipate that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Institutional Trading of KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for about 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of KALA BIO in a report on Friday, November 15th.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.